Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported that to complement the concentration in near-rare and rare neuropsychiatric problems, Liza A. Squires, MD has been engaged to the newly created profile of Chief Medical Officer reporting to President Terri Browning Sebree. Dr. Squires will look after the firm’s clinical strategy and activities, such as clinical research, regulatory affairs, drug safety and surveillance and medical affairs.
Dr. Squires has extensive experience of more than 25 years in neuropsychiatric and rare disorders. She was recently the VP and Therapeutic Area Head of Neuroscience segment for Aevi Genomic Medicine. She served as CMO for Lumos Pharma, where she advanced an accelerated development plan for an ultra-orphan population. She spent almost 10 years at Shire Pharmaceuticals, concluding in her tenure as Product General Manager and VP of R&D of CNS Early Pipeline. Zynerba reported that Dr. Squires was the Director of Pediatric Neurology at DeVos Children’s Hospital.
Terri Browning Sebree, the President of Zynerba, expressed that they are delighted to report the addition of Dr. Squires as company’s new Chief Medical Officer. She brings extensive experience from clinical, medical, and biotechnology segment in rare neuropsychiatric and pediatric neurology disorders. Sebree added that they have a remarkable team at company, with an established track record in orphan medicines, transdermal delivery and CNS disorders. Dr. Squires insights and pediatric neurology background will complement their team well. They welcome her to the firm and look forward to her utmost contributions to the advancement of their pipeline.
In the last trading session, the stock price of Zynerba declined more than 5% to close the day at $11.87. The decline came at a share volume of 532,410 compared to average share volume of 632,735. Post the recent decline, the market cap of firm was noted at $170.1 million. The stock has been trading in red for the year.